Abstract. The aim of this study was to test the effect of actinomycin D on the expression of selected genes and to elucidate possible components of its apoptotic pathway in mouse embryos. Selected mRNAs and Trp53 protein were examined in blastocysts cultured for 24 h in vitro with or without the presence of a high concentration of actinomycin D. In all tested genes, the relative quantities of mRNA were significantly lower in treated blastocysts than in controls. The mRNA quantities of H2afz, Actb, Bax, Bad and Bcl2 were reduced at a similar rate, but the decreases in Bcl2l2 and Trp53 mRNA were significantly greater. Treatment with actinomycin D also changed the ratio between the mRNA levels of some pro-apoptotic and anti-apoptotic genes: the Bad/Bcl2l2 and the Bax/Bcl2l2 ratios were on average 4.39 and 2.66 times higher in the treated embryos than in the controls, respectively. Generally, treatment led to developmental arrest and significant increase in the incidence of cells with typical apoptotic features. However, its effect on Trp53 protein expression was not significant. The results suggest that mechanisms beyond the apoptotic effect of actinomycin D might include specific changes in the expression of pro-apoptotic and anti-apoptotic genes, shifting the expression ratio in favor of the pro-apoptotic ones. The results also show that the role of Trp53 is probably not crucial in this apoptotic pathway. Key words: Apoptotic genes, Blastocyst, Induced apoptosis, Trp53 protein (J. Reprod. Dev. 55: [576][577][578][579][580][581][582] 2009) t is now well understood that cell death is a fundamental aspect of normal development of almost all organisms. In mammalian preimplantation embryos, both spontaneous and induced apoptotic processes have been documented, showing morphological and biochemical specificity when compared with fullydifferentiated cell populations [reviewed in 1, 2]. Nowadays, the molecular mechanisms of these processes are the main objectives of cell death research.
t is now well understood that cell death is a fundamental aspect of normal development of almost all organisms. In mammalian preimplantation embryos, both spontaneous and induced apoptotic processes have been documented, showing morphological and biochemical specificity when compared with fullydifferentiated cell populations [reviewed in 1, 2] . Nowadays, the molecular mechanisms of these processes are the main objectives of cell death research.
Since apoptosis is a self-directed physiological process based on a genetic mechanism, regulation of both spontaneous and induced cell death is dependent on the expression of pro-and anti-apoptotic genes. In most cases, the ratio of pro-apoptotic to anti-apoptotic Bcl2 homologues within a cell determines whether the cell will survive or die [3] .
Anti-apoptotic proteins (Bcl2, Bcl2l2, Bcl2l1 (Bcl-XL)) block passive diffusion of cytochrome c from mitochondria, and pro-apoptotic proteins (Bax, Bak1, Bok (Mtd)) conduct its active release. The remaining pro-apoptotic proteins (Bad, Bid, Hrk) lack channelforming domains (BH1 and BH2), and only the BH-3 domain (which delineates the core residues for homo-and heterodimerization) is important for their activity. The activity of Bcl2 family proteins is regulated via transcriptional and translational control, post-translational modifications and intracellular localization or storage [4] . Whereas Bax and Bak1 play a central role in most forms of apoptosis, BH3-only proteins appear to modulate apoptosis through cell type-specific and signal-specific pathways [5] .
The Trp53 protein (also known as p53) is involved in various events preventing the further development and reproduction of cells with a damaged genome. When cell DNA is damaged, Trp53 protein is activated and mediates temporary arrest of the cell cycle in the G1 phase, giving the cell sufficient time to repair its DNA [6] . If the DNA damage is too severe to be repaired, Trp53 initiates cell death by stimulating the Fas receptor complex and Bax protein on the mitochondrial membrane, leading to cytochrome c release and caspase-3 activation [7] .
In mouse and rat preimplantation embryos, the involvement of several pro-apoptotic and anti-apoptotic genes in an apoptotic pathway triggered by hyperglycemic stress has been described [8] [9] [10] . It is known that blastocysts under similar in vivo and in vitro hyperglycemic conditions (streptozotocin-induced diabetes and cultures with high concentrations of D-glucose) show higher incidence of apoptosis characterized by increased DNA fragmentation [8] . Functional studies using gene knockout or antisense approaches have shown that Bax is required for this induction of apoptosis, under the control of Trp53, whereas Bcl2 has a protective role in this case [9, 10] . In any case, the involvement of these genes in other apoptotic pathways has been studied only marginally.
The purpose of our research was to evaluate possible molecular mechanisms of an apoptotic pathway triggered by actinomycin D. Actinomycin D is a potent inducer of apoptosis in a variety of cells in vitro and in vivo and is used in cancer therapy [11, 12] . It is an antibiotic that is able to bind DNA duplexes and inhibit RNA synthesis. The ability of actinomycin D to induce apoptosis in mouse, bovine, rabbit and Xenopus laevis preimplantation embryos has been demonstrated previously [2, [13] [14] [15] [16] . Furthermore, when compared with TNF-α, actinomycin D shows higher efficiency and a stronger and quicker inducing effect accompanied by low variability in its effectiveness [2] . Thus, we decided to examine the effect of a high concentration (i.e., apoptosis inducing) of actino-mycin D on the expression of selected genes in mouse preimplantation embryos cultured in vitro. The messenger RNA (mRNA) quantities of two "housekeeping" genes [H2afz (H2A histone family member Z), Actb (Actin beta, cytoplasmic)], two proapoptotic genes [Bax (Bcl2-associated X protein), Bad (Bcl-associated death promoter)], two anti-apoptotic genes [Bcl2 (B-cell leukemia/lymphoma 2), Bcl2l2 (Bcl2-like 2)] and the Trp53 (Transformation related protein 53) gene were determined in the blastocysts. The expression of Trp53 was also evaluated at the protein level, since it is widely accepted that the inductive response of this gene is mainly post-transcriptional [for a review, see 17 and 18] .
Materials and Methods

Embryo recovery and culture
Female mice (ICR strain, Velaz, Prague, Czech Republic; 4 weeks old) underwent a superovulation treatment with pregnant mare's serum gonadotropin (eCG 5 IU ip; Folligon, Intervet international, Boxmeer, Holland) followed 47 h later by administration of human chorionic gonadotropin (hCG 5 IU ip; Pregnyl, Organon, Oss, Holland). The females were mated with males of the same strain. Embryos at the blastocyst stage were flushed from the uteri of animals euthanized by cervical dislocation using a flushingholding medium (FHM) 90 h after hCG administration. The embryos were then pooled, randomly divided into two groups, washed in KSOM culture medium (Specialty Media Group, Phillipsburg, NJ, USA), transferred to culture drops (1 embryo / 1 μl KSOM) containing no additional supplement (control group) or actinomycin D at 0.05 μg/ml (experimental group) and cultured under standard conditions (5% CO2, atmospheric O2 and 37 C) for 24 h. Immediately after culture, approximately 90 to 100 of both untreated and treated blastocysts were collected for real-time RT-PCR quantification of mRNA expression, approximately 30 of both untreated and treated blastocysts were collected for two cell death assays and another 15 of both untreated and treated blastocysts were subjected to immunocytochemical staining for Trp53 protein.
Three consecutive experiments were performed.
All animal experiments were reviewed and approved by the Ethical Committee for animal experimentation of the Institute of Animal Physiology, approved by the State Veterinary and Food Administration of the Slovak Republic, and were performed in accordance with Slovak legislation based on Directive 86/609/EEC concerning the protection of animals used for experimental and other scientific purposes.
Real-time RT-PCR quantification of mRNA expression
Total RNA was extracted from batches of 90 to 100 mouse blastocysts (the number of embryos in each pool was exactly determined) using TRIzol Reagent (Invitrogen Life Technologies, Karlsruhe, Germany) according to the manufacturer's instructions. To correct differences in RNA recovery and loading of RT-PCR reactions, 0. and 0.5 mg acetylated BSA. The reaction was terminated by heating at 95 C for 5 min. To check for the presence of genomic DNA contamination in the RNA preparations, reverse transcriptase negative control reactions (no reverse transcriptase in the reaction) were carried out in parallel using a portion of each RNA sample. The cDNA preparations were then cleaned by ethanol precipitation, and the cDNA pellets were diluted in an appropriate amount of 10 mM Tris (pH 8.3) so that 1 μl of the cDNA corresponded to 2.5 embryo (and 0.5 pg luciferase mRNA) equivalents.
Amplification reactions were carried out in 20 μl volumes containing 0.8 μl of cDNA (or 4 μl of cDNA in the case of Bcl2 amplification), 0.8 μl of the appropriate primer set (final primer concentration: 0.4 μM) and 10 μl of 2x SYBR Green / ROX PCR mix (PA-012, SuperArray Bioscience, Frederick, MD, USA). The following primer sets (obtained from SuperArray Bioscience) were used: RT 2 PCR primer sets for mouse H2afz (#PPM03118A), Actb (#PPM02945A), Bax (#PPM02917A), Bad (#PPM02916A), Bcl2 ( # P P M 0 2 9 1 8 A ) , B c l 2 l 2 ( # P P M 0 2 9 1 9 A ) a n d T r p 5 3 (#PPM02931A). All primers provided PCR products of expected sizes (checked by agarose gel electrophoresis).
The primers for amplification of Bcl2 and Bcl2l2 mRNAs (SuperArray Bioscience) were designed into coding regions of the genes; the messenger RNAs of the two genes have very long 3' untranslated regions (in Bcl2, containing two potential polyA signals; see GenBank accession numbers NM_009741 and NM_007537), which can result in a low yield of sufficiently long cDNA if oligo dT is used for reverse transcription. Since we obtained high Ct values using these primers (especially in embryos treated with actinomycin D), we designed our own primers for the Bcl2l2 gene, which we located near to the mRNA 3' end. The sequences of our Bcl2l2 primers were as follows: 5'-CTTAGG-GAGATGAGGGAGTGG-3' and 5'-ATGGGAAGGGTA-GAGCAGAGA-3'. The primers amplified a 218-bp PCR product that gave DNA fragments of expected sizes (53, 13, 93 and 59 bp) after digestion with Alu I. For amplification of luciferase (Luc) mRNA, we designed primers with the following sequences: 5'-GCTTACTGGGACGAAGACGAAC-3' and 5'-CTTGACTGGC-GACGTAATCCAC-3'. The primers amplified a 247-bp PCR product that gave DNA fragments of expected sizes (97, 28 and 122 bp) after digestion with Taq I.
PCR amplifications were performed in an Mx 3000P real-time PCR system (Stratagene, La Jolla, CA, USA). For most amplifications, an initial step at 95 C for 15 min (DNA denaturation and hot start DNA polymerase activation) was followed by 40 cycles at 95 C for 20 sec (denaturation), 60 C for 60 sec (annealing/extension) and 80 C for 30 sec (acquisition of fluorescence). The following modifications of the thermocycling conditions were used for some genes: 45 amplification cycles were used for Bcl2, Bcl2l2 and Trp53, an elevated temperature in the annealing/extension step was used for Bcl2l2 (64 or 68 C), elevated "acquisition temperatures" were used for Bax, Luc (82 C) and Bcl2 (84 C) and a lowered "acquisition temperature" was used for H2afz (76 C). Amplification specificity was checked by generation of a melting curve using 41 cycles with temperature increments of 1 C (starting with 55 C) and a fluorescence measurement in each cycle.
The fluorescence data obtained from amplifications were transformed to the values of relative mRNA quantity using three methods of analysis: the LinRegPCR-Ct method, Liu & Saint exp method and DART-PCR method [19] [20] [21] [22] . All the methods showed similar results (the quantification results obtained with the LinReg-PCR-Ct method are presented). The expression of mouse genes was normalized with the external control, luciferase mRNA in each sample (i.e., the mRNA relative quantity of each mouse gene was divided by the Luc mRNA relative quantity), and all mRNA amounts were evaluated on a per embryo basis as well as on a per cell basis (considering the significantly lower cell number in actinomycin D-treated embryos).
Cell death assay
For detection of cell death, two staining methods were used: TUNEL/propidium iodide (PI) fluorescence staining, which enabled morphological assessment of nuclei (M-, normal nuclei; M+, condensed or fragmented nuclei), detection of specific DNA degradation in the nucleoplasm (T+/-, positive/negative TUNELlabeling) and assessment of cell viability (PI+/-, positive/negative propidium iodide staining) and TUNEL/caspase-3 fluorescence staining, which enabled morphological assessment of nuclei (M+/-), detection of specific DNA degradation in the nucleoplasm (T+/-) and detection of active caspase-3 in the cytoplasm (C3+/-, presence/ absence of IHC visualized enzyme). Both detection methods have been described previously [2] .
Briefly, blastocysts subjected to TUNEL/PI staining were initially incubated in culture medium containing 10 μg/ml propidium iodide (Sigma-Aldrich). They were then fixed in 4% paraformaldehyde (Merck, Darmstadt, Germany), permeabilized in 0.5% Triton X-100 (Sigma-Aldrich) and incubated in 10 μl of TdT (terminal deoxynucleotidyl transferase) and 90 μl of fluoresceinconjugated dUTP (TUNEL, In Situ Cell Death Detection Kit; Roche, Penzberg, Germany). Blastocysts subjected to TUNEL/caspase-3 staining were fixed in 4% paraformaldehyde immediately after culture. They were then washed in 0.3% Triton X-100, permeabilized in 1% Triton X-100 and subjected to TUNEL reaction. TUNEL-reacted embryos were blocked in a buffer containing 5% normal goat serum (Invitrogen), incubated overnight with a primary anti-active-caspase-3 antibody (polyclonal rabbit Cleaved Caspase-3 (Asp175) antibody; Cell Signaling Technology, Danvers, MA, USA), washed again and then incubated with a Texas Red-conjugated secondary antibody (Goat Anti-Rabbit IgG; Jackson ImmunoResearch, West Grove, PA, USA).
Finally, all samples were counterstained with Hoechst 33342 (20 μg/ml). Embryos were then mounted on slides with Vectashield (Vector Laboratories, Burlingame, CA, USA) and observed under a fluorescence microscope at × 400 magnification (BX 51 Olympus, Japan).
Immunocytochemical staining for Trp53 protein
Embryos were washed three times in PBS supplemented with bovine serum albumin (BSA; Sigma-Aldrich), fixed in 4% paraformaldehyde for 1 h and then permeabilized in 0.1% Triton X-100 for 10 min at room temperature. They were then blocked in 3% donkey serum (Calbiochem, San Diego, CA, USA, or Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 4 h, washed and stained overnight at 4 C with primary antibodies from two sources: anti-p53 (Ab-7) sheep polyclonal antibody (1:500; Calbiochem; which has previously been used in mouse preimplantation embryos [23] ) or anti-p53 (M-19) goat polyclonal antibody (1:100; Santa Cruz Biotechnology; to our knowledge, not previously used in embryos). The embryos were then washed again and incubated with the following FITC-conjugated secondary antibodies: donkey anti-sheep IgG (Jackson ImmunoResearch, West Grove, PA, USA) or donkey anti-goat IgG (Jackson ImmunoResearch), respectively, for the used primary antibodies. Finally, they were washed in PBS (with BSA), counterstained with Hoechst 33342 (20 μg/ml), mounted on slides with Vectashield and observed under a fluorescence microscope at × 400 magnification (BX 51 Olympus, Japan). For each image recording, the same exposure parameters were used. An antibody staining control was performed for each immunofluorescence experiment. Omission of the primary antibody in the staining procedure resulted in complete absence of immunofluorescence staining.
Statistics
Statistical analysis was performed using Statistica (StatSoft, Tulsa, OK, USA). The Mann-Whitney test was used for the comparison of differences in mRNA relative quantities and for comparison of differences in the ratio of pro-apoptotic / anti-apoptotic gene mRNA quantities between actinomycin D-treated and control embryos. The Kruskal-Wallis test (K-W) was used for the comparison of differences in fold change of mRNA quantities of the examined genes after the actinomycin D treatment. The Student's t-test was used for comparison of differences in mean numbers of cells (nuclei) per blastocyst. The results are expressed as mean values ± SEM. Standard chi-square tests were used for comparison of differences in distribution of embryos with apoptotic cells and for comparison of differences in distribution of dead cells. Differences of P<0.05 were considered significant.
Results
Embryo growth and cell death incidence
Actinomycin D treatment arrested the development of all blastocysts cultured for 24 h in vitro, leading to an approximately 2-fold decrease of the blastocyst cell number (Table 1) . It also significantly increased the incidence of dead cells (54.66 vs. 3.98%, when compared with the controls). As shown by the viability assay, the majority of these dead cells were of apoptotic origin. The presence of all three evaluated apoptotic features (condensed or fragmented nuclear morphology, specific DNA degradation in the nucleoplasm and active caspase-3 in the cytoplasm) was observed in 42.95% of the actinomycin D-treated blastomeres.
Expression of mRNA
The examined messenger RNAs produced a measurable fluorescent signal in PCR reactions containing cDNA amounts representing the equivalent of two control-or actinomycin Dtreated embryos. In the case of Bcl2, the amount of cDNA had to be increased 5-fold (i.e., to the equivalent of 10 embryos) to obtain a reliably measurable fluorescent signal. In all tested genes, the relative quantities of mRNA in blastocysts treated with actinomycin D were significantly (P<0.05) lower than in the control blastocysts (evaluated on a per embryo basis as well as on a per cell basis, data not shown). As shown in Fig. 1 , the mRNA quantities of H2afz, Actb, Bax, Bad and Bcl2 were reduced at a similar rate (about 8-fold; with slightly greater reduction in Actb and lesser reduction in Bad), but the decreases in Bcl2l2 and Trp53 mRNA were significantly greater (on average an approximately 24-fold decrease in mRNA quantity). Similar results were found after evaluation on a per cell basis (an approximately 4.5-fold decrease in H2afz, Actb, Bax, Bad and Bcl2 versus an approximately 13-fold decrease in Bcl2l2 and Trp53, Fig. 2) .
Estimation of the ratio of Bax and Bad mRNA quantity (proapoptotic genes) to Bcl2l2 mRNA quantity (an anti-apoptotic gene) showed that the ratio was significantly higher in blastocysts treated with actinomycin D than in control blastocysts ( Fig. 3a and 3b) . It is necessary to stress that the ratios were derived from relative quantities of mRNA, which were expressed in arbitrary units, and do not reflect the ratios of absolute quantities of mRNAs in cells. For this reason, only comparison of changes in the ratios between control and actinomycin D samples is possible; the Bad / Bcl2l2 and Bax / Bcl2l2 ratios were on average 4.39 and 2.66 times higher in embryos treated with actinomycin D than in control embryos, respectively ( Fig. 3a and 3b) .
Expression of Trp53 protein
There were no obvious differences in the outcomes of the staining protocols using two different anti-p53 primary antibodies. Control blastocysts showed the presence of immunocytochemical staining in the majority of their cells. The signal was localized in both the nucleoplasm and cytoplasm, and its intensity was slightly increased in some cells that showed fragmented nuclear morphology (Fig. 4) . Apoptotic cells without increased signals were also observed. Actinomycin D-treated embryos similarly showed the presence of immunocytochemical staining in the majority of their cells. A slightly increased staining signal was observed in a portion of normal cells and in a portion of cells with fragmented nuclear morphology (Fig. 4) , and the proportion differed from embryo to embryo.
Discussion
Gene expression in normal blastocysts
The presence of Bcl2, Bcl2l2 (Bcl-W), Bax and Trp53 (p53) mRNAs has been previously documented at all stages of mouse preimplantation development, with de novo expression from the late 2-cell stage [24] [25] [26] . Estimates of Bad mRNA expression have been contradictory. While Jurisicova et al. [24] described its presence at all stages of mouse preimplantation development, with de novo expression from the 8-cell stage, Exley et al. [26] found Bad mRNA to be most often undetectable. Interestingly, in human embryos, Bad has been proposed as a key regulatory protein in preimplantation apoptosis [27] .
In our experiments, we detected mRNAs for Bcl2, Bcl2l2, Bax, Bad and Trp53 in both control blastocysts and actinomycin Dtreated embryos. However, in the case of Bcl2, the sample amount had to be increased to obtain a reliable measurable fluorescent signal.
Reliable detection of Bcl2 gene during preimplantation development seems to depend on the technique used. PCR amplification combined with radioactive dot blot hybridization (QADB) detected Bcl2 at low copy number at all stages of development [24] , but conventional RT-PCR detected Bcl2 only in some pooled groups of embryos [26] , and in situ hybridization detected Bcl2 only in 2% of the cells of the blastocyst [10] . Comparison of Bcl2 and Bcl2l2 mRNA quantities during mouse preimplantation development reveals higher expression of Bcl2l2 mRNA, especially at later developmental stages. Expression of Bcl2l1 (Bcl-XL, another member of the Bcl2 family with anti-apoptotic properties) predominates over the expressions of Bcl2 and Bcl2l2 until the mid 2-cell stage, but afterwards it decreases markedly and falls below the Bcl2l2 level at the blastocyst stage [24] . These results suggest an important role for Bcl2l2 and Bcl2l1 in the inhibition of early embryonic cell death. Detection of Bcl2l2 mRNA in 100% of blastocyst sample replicates, Bcl2l1 in 80% of blastocyst sample replicates and Bcl2 only in 56% of blastocyst sample replicates [26] supports this opinion.
Gene expression in actinomycin D-treated blastocysts
Previous studies have demonstrated that various external (or internal) impacts (e.g., culture in vitro, vitrification, treatment with survival factors or toxic substances) can affect both mRNA and protein expression of Bcl2 family genes in mouse preimplantation embryos [23, [28] [29] [30] [31] . Treatment with actinomycin D exemplifies a strong external impact with stable detrimental effects represented by specific morphological and biochemical changes [2, 13] . It is well known that actinomycin D intercalates into DNA and interferes with RNA polymerases and DNA topoisomerases. It first binds to locations with very actively transcribed genes [32] , causes down-regulation of RNA synthesis and then usually induces mitochondria-dependent apoptosis characterized by the release of cytochrome c and activation of downstream effector caspases 3, 6 and 7 [33] . At low concentrations, actinomycin D acts as an inhibitor of ribosomal gene transcription. Somatic cells (Hela) treated with low concentrations of actinomycin D show occasional appearance of apoptosis. Treatment impairs rRNA synthesis, while synthesis of pre-mRNAs is contrastingly active [34] . At high concentrations, actinomycin D causes damage to DNA and inhibits transcription from all three classes of RNA polymerase promoters. Somatic cells (Hela) treated with high concentrations of actinomycin D show massive appearance of apoptosis, represented by phosphatidylserine flip, chromatine condensation, cell blebbing and specific DNA degradation. In these cells, both rRNA synthesis and pre-mRNA maturation are impaired. However, transcription of hnRNAs is maintained in the residual areas of diffused non-condensed chromatin up to advanced apoptotic stages [34] . Mouse preimplantation embryonic cells treated with high concentrations of actinomycin D also show massive appearance of cell death with characteristic signs of apoptosis: chromatin marginalization, degeneration of cytoplasm, nuclear fragmentation, specific DNA degradation, phosphatidylserine flip and activation of caspase 3 [2, [13] [14] [15] , which was also documented in the present study. The inhibition of rRNA synthesis after treatment with high concentrations of actinomycin D has also been demonstrated in porcine and bovine blastocysts [15, 35] .
The data presented in our experiment (i.e., significantly decreased mRNA levels in all seven measured genes in actinomycin D-treated blastocysts) are in accordance with previous results describing actinomycin D as a strong inhibitor of transcription. However, our results show that the decreases of mRNA levels in the embryonic cells were not the same in the examined genes. Bcl2l2 and Trp53 showed markedly higher reductions in mRNA levels after actinomycin D treatment than the other genes. It is generally accepted that the main mechanism by which actinomycin D inhibits RNA synthesis is blocking the DNA template function by intercalating into DNA, and some sequence preferences in actinomycin D binding have been demonstrated [for a review, see 36 and 37] . In addition, other mechanisms for inhibiting RNA synthesis by actinomycin D have also been proposed [38, 39] . On the other hand, the differences in the mRNA levels found in our experiment could result not only from changes in transcription of the measured genes but also from differing stability of particular mRNAs.
Induction of transcription of pro-apoptotic members of the Bcl2-family by Trp53 is a mechanism generally proposed for Trp53-regulated apoptosis [40] . However, the dependence of Trp53-mediated apoptosis on transcriptional activation is controversial in some cell types, and Trp53 protein has also been suggested to have transcription-independent activity [41] [42] [43] . In preimplantation embryonic cells, the involvement of Trp53 in the apoptotic pathway triggered by actinomycin D is questionable. In our experiment, the drop in Trp53 mRNA was not followed by a decrease in Trp53 protein amount. This indicates that, on the one side, treatment with actinomycin D lowered the Trp53 mRNA amount, but on the other side, it probably stabilized the Trp53 protein (the protein displays a very short half-life in unstressed cells [for a review, see 17 and 18]), keeping its level unchanged. This increase in Trp53 protein stability after treatment with actinomycin D has been shown in various cell types [33, [44] [45] [46] .
Our results indicate that a mechanism contributing to the apoptosis-inducing character of actinomycin D might be connected with the change in ratio between the mRNA levels of some pro-apoptotic and anti-apoptotic genes in embryonic cells. On the other hand, the lack of difference in level of Trp53 protein between the control and actinomycin D-treated blastocysts suggests that Trp53 does not play a significant role in this apoptotic pathway. This study extends our knowledge about the expression of various components of the apoptotic cascade in preimplantation embryos. Furthermore, it describes the involvement of these components in the apoptotic pathway triggered by a standardized inductor and thus elucidates an important aspect of the physiological abilities of embryonic cells.
